Mood Disorders Associated with Interferon Treatment: Theoretical and Practical Considerations

Abstract

Spanish

French

OBJECTIVE:

To review the theoretical and clinical aspects of mood disorders associated with interferon treatment and discuss their management.

DATA SOURCES:

Pertinent and selected laboratory/clinical studies, review articles, letters, abstracts, and book chapters on behavioral and mood-related adverse effects of interferons published in English-language journals in the past two decades were identified by MEDLINE (June 1980–June 2000) and manual searches.

DATA SELECTION AND DATA EXTRACTION:

All of the publications identified were reviewed, and the relevant data were included. Studies not using criteria for psychiatric diagnosis or instruments for psychiatric monitoring were excluded.

DATA SYNTHESIS:

Clinical observations and limited research data suggest that interferon treatment may be associated with mood disorders. Mood-related symptoms induced by interferons emerge in a few days or weeks and tend to be dose dependent. Their severity may necessitate discontinuation of interferon therapy and/or the use of antidepressant or antimanic agents. The mechanisms responsible for inducing or exacerbating mood disorders in interferon-treated patients have not been elucidated. There is limited evidence implicating alterations in the serotonin system.

CONCLUSIONS:

While interferon therapy may trigger or induce mood-related symptoms, preexisting or stable concurrent mood disorders in remission do not necessarily constitute a contraindication to treatment with interferons. Mood disorders associated with interferon treatment can present clinical challenges. However, they may promote our understanding of mood disorders in the context of the current biologic theories of depression and mania.

Keywords

antidepressants cytokines depression interferons mania mood disorders

Get full access to this article

View all access options for this article.

References

Oppenheim

Saklatvala

. Cytokines and their receptors. In: Oppenheim

Rossio

Gearing

AJH

, eds. Clinical applications of cytokines. Role in pathogenesis, diagnosis and therapy. New York: Oxford University Press, 1993:3–15.

Finter

. The naming of cats — And alpha interferons (comment). Lancet 1996;348:348–9.

American Hospital Formulary Service drug information. Bethesda, MD: American Society of Health-System Pharmacists, 2000:953–85.

Mosby's GenRx. St. Louis, MO: Mosby, 2000;904–30.

De Maeyer

De Maeyer-Guignard

. Interferons. In: Thomson

, ed. The cytokine handbook. 3rd ed. San Diego, CA: Academic Press, 1998:491–516.

Mattson

Niiranen

Iivanainen

Farkkila

Bergstrom

Holsti

Neurotoxicity of interferon. Cancer Treat Rep 1983;67:958–61.

Smith

Norris

Palmer

Bernhardt

Wills

. Distribution of alpha interferon in serum and cerebrospinal fluid after systemic administration. Clin Pharmacol Ther 1985;37:85–8.

Shibata

Blatteis

. Human recombinant tumor necrosis factor and interferon affect the activity of neurons in the organum vasculosum laminae terminalis. Brain Res 1991;562:323–6.

Yamada

Yamanaka

. Microglial localization of α-interferon receptor in human brain tissues. Neurosc Lett 1995;189:73–6.

10.

Valente

Ozmen

Novelli

Guena

Palestro

Forni

Distribution of interferon-γ receptor in human tissues. Eur J Immunol 1992;22:2403–12.

11.

Birmanns

Saphier

Abramsky

. α-Interferon modifies cortical EEG activity: Dose-dependence and antagonism by naloxone. J Neurol Sci 1990;100:22–6.

12.

Dafny

Prieto-Gomez

Dong

W-Q

Reyes-Vazquez

. Interferon modulates neuronal activity recorded from the hypothalamus, thalamus, hippocampus, amygdala and the somatosensory cortex. Brain Res 1996;734:269–74.

13.

Smith

Tyrrell

Coyle

Higgins

. Effects of interferon alpha on performance in man: A preliminary report. Psychopharmacology 1988;96:414–6.

14.

Smedley

Katrak

Sikora

Wheeler

. Neurological effects of recombinant human interferon. Br Med J 1983;286:262–4.

15.

Rohatiner

AZS

Prior

Burton

Smith

Balkwill

Lister

. Central nervous system toxicity of interferon. Br J Cancer 1983;47:419–22.

16.

Centers for Disease Control and Prevention. Recommendations for prevention and control of hepatitis C virus (HCV) infection and HCV-related chronic disease. MMWR Morb Mortal Wkly Rep 1998;47:1–39.

17.

Compston

. Treatment and management of multiple sclerosis. In: Compston

Ebers

Lassmann

McDonald

Matthews

Wekerle

, eds. McAlpine's multiple sclerosis. 3rd ed. London: Churchill Livingstone, 1998:437–98.

18.

Zdilar

Franco-Bronson

Buchler

Locala

Younossi

. Hepatitis C, interferon alfa, and depression. Hepatology 2000;31:1207–11.

19.

Dieperink

Willenbring

. Neuropsychiatric symptoms associated with hepatitis C and interferon alpha: A review. Am J Psychiatry 2000;157:867–76.

20.

Dusheiko

. Side effects of alpha interferon in chronic hepatitis C. Hepatology 1997;26(suppl 1):112S–21S.

21.

Poynard

Leroy

Cohard

Thevenot

Mathurin

Opolon

Meta-analysis of interferon randomized trials in the treatment of viral hepatitis C: Effects of dose and duration. Hepatology 1996;24:778–89.

22.

Farkkila

Iivanainen

Roine

Bergstrom

Laaksonen

Niemi

M-L

Neurotoxic and other side effects of high-dose interferon in amyotrophic lateral sclerosis. Acta Neurol Scand 1984;70:42–6.

23.

Iivanainen

Laaksonen

Niemi

M-L

Farkkila

Bergstrom

Mattson

Memory and psychomotor impairment following high-dose interferon treatment in amyotrophic lateral sclerosis. Acta Neurol Scand 1985;72:475–8.

24.

Adams

Quesada

Gutterman

. Neuropsychiatric manifestations of human leukocyte interferon therapy in patients with cancer. JAMA 1984;252:938–41.

25.

McDonald

Mann

Thomas

. Interferons as mediators of psychiatric morbidity. An investigation in a trial of recombinant a interferon in hepatitis-B carriers. Lancet 1987;2:1175–8.

26.

Renault

Hoofnagle

Park

Mullen

Peters

Jones

Psychiatric complications of long-term interferon alfa therapy. Arch Intern Med 1987;147:1577–80.

27.

Fent

Zbinden

. Toxicity of interferon and interleukin. Trends Pharmacol Sci 1987;8:100–5.

28.

Davis

Balart

Schiff

Lindsay

Bodenheimer

Jr. Perrillo

R P

Treatment of chronic hepatitis C with recombinant interferon alfa. A multicenter randomized, controlled trial. N Engl J Med 1989;321:1501–6.

29.

Hoofnagle

Di Bisceglie

. The treatment of chronic viral hepatitis. N Engl J Med 1997;336:347–56.

30.

Bader

. Viral hepatitis: practical evaluation and treatment. Seattle, WA: Hogref and Huber, 1997.

31.

Janik

Steis

. Interferon therapy for malignant and nonmalignant disease. In: Oppenheim

Rossio

Gearing

AGH

, eds. Clinical applications of cytokines. Role in pathogenesis, diagnosis and therapy. New York: Oxford University Press, 1993:135–45.

32.

Miyaoka

Otsubo

Kamijima

Ishii

Onuki

Mitamura

. Depression from interferon therapy in patients with hepatitis C (letter). Am J Psychiatry 1999;156:1120.

33.

Mohr

Goodkin

Likosky

Gatto

Baumann

Rudick

. Treatment of depression improves adherence to interferon beta-1b therapy for multiple sclerosis. Arch Neurol 1997;54:531–3.

34.

Rudick

Cohen

Weinstock-Guttman

Kinkel

Ransohoff

. Management of multiple sclerosis. N Engl J Med 1997;337:1604–11.

35.

Durelli

Bongioanni

Cavallo

Ferrero

Ferri

Ferrio

Chronic systemic high-dose recombinant interferon alfa-2a reduces exacerbation rate, MRI signs of disease activity, and lymphocyte interferon gamma production in relapsing—remitting multiple sclerosis. Neurology 1994;44:406–13.

36.

Borras

Rio

Porcel

Barrios

Tintore

Montalban

. Emotional states of patients with relapsing—remitting MS treated with interferon beta-1b. Neurology 1999;52:1636–9.

37.

Jacobs

Rudick

Simon

. Extended observations on MS patients treated with IM interferon-beta1a (Avonex): Implications for modern MS trials and therapeutics. J Neuroimmunol 2000;107:167–73.

38.

Kwon

Prineas

. Blood—brain barrier abnormalities in longstanding multiple sclerosis lesions. An immunohistochemical study. J Neuropathol Exper Neurol 1994;53:625–36.

39.

Renault

Hoofnagle

. Side effects of alpha interferon. Semin Liver Dis 1989;9:273–7.

40.

Hoofnagle

Di Bisceglie

Waggoner

Park

. Interferon alfa for patients with clinically apparent cirrhosis due to chronic hepatitis B. Gastroenterology 1993;104:1116–21.

41.

Borghesio

Rosina

Di Marco

Mangia

Accogli

Vandelli

Long term treatment of chronic hepatitis D with lymphoblastoid interferon: 10 MU vs. 5 MU. An interim report of a randomized controlled trial (abstract). Hepatology 1995;22:397.

42.

O'Conner

NT-J

. Interferon b and suicide in multiple sclerosis (letter). Lancet 1996;347:1417–8.

43.

Yoyokama

Kimura

Shigemura

. Psychiatric side effects of interferon. J Toxicol Sci 1996;21:93–6.

44.

Fukunishi

Tanaka

Maruyama

Takahashi

Kitaghishi

Ueshima

Burns in a suicide attempt related to psychiatric side effects of interferon. Burns 1998;24:581–3.

45.

Rosenstein

Lerner

Cai

. More on the depressive effects of interferon alfa (letter). N Engl J Med 1999;341:849.

46.

Levenson

Fallon

. Fluoxetine treatment of depression caused by interferon-α. Am J Gastroenterol 1993;88:760–1.

47.

Valentine

Meyers

Kling

Richelson

Hauser

. Mood and cognitive side effects of interferon-α therapy. Semin Oncol 1998;25(suppl 1):30–47.

48.

Goldman

. Successful treatment of interferon alfa—induced mood disorder with nortriptyline (letter). Psychosomatics 1994;35:412–3.

49.

Hakozaki

Shirahama

Katou

Nakagawa

Oba

Mitamura

. A controlled study to determine the optimal dose regimen of interferon-α 2b in chronic hepatitis C. Am J Gastroenterol 1995;90:1246–9.

50.

Nozaki

Takagi

Takaoka

Takata

Yoshida

. Psychiatric manifestations accompanying interferon therapy for patients with chronic hepatitis C: An overview of cases in Japan. Psychiatry Clin Neurosci 1997;51:175–80.

51.

Lerner

Stoudemire

Rosenstein

. Neuropsychiatric toxicity associated with cytokine therapies. Psychosomatics 1999;40:428–35.

52.

Van Thiel

Friedlander

De Maria

Molloy

Kania

Colantoni

. Treatment of chronic hepatitis C in individuals with pre-existing or confounding neuropsychiatric disease. Hepatogastroenterology 1998;45:328–30.

53.

Gleason

Yates

. Five cases of interferon-alpha—induced depression treated with antidepressant therapy. Psychosomatics 1999;40:510–2.

54.

Valentine

Meyers

. Successful treatment of interferon-α–induced mood disorder with nortriptyline (letter). Psychosomatics 1995;36:418–9.

55.

Prior

Chue

. Psychotic depression after stopping interferon-α (letter). J Clin Psychopharmacol 1999;19:385–6.

56.

McAllister-Williams

Young

Menkes

. Antidepressant response reversed by interferon (letter). Br J Psychiatry 2000;176:93.

57.

Suter

Westmoreland

Sharbrough

Hermann

Jr.

Electroencephalographic abnormalities in interferon encephalopathy: A preliminary report. Mayo Clin Proc 1984;59:847–50.

58.

Meyers

Scheibel

Forman

. Persistent neurotoxicity of systematically administered interferon-alpha. Neurology 1991;41:672–6.

59.

Pavol

Meyers

Rexer

Valentine

Mattis

Talpaz

. Pattern of neurobehavioral deficits associated with interferon alfa therapy for leukemia. Neurology 1995;45:947–50.

60.

Adams

Fernandez

Mavligit

. Interferon-induced organic mental disorders associated with unsuspected pre-existing neurologic abnormalities. J Neurooncol 1988;6:355–9.

61.

Janssen

HLA

Brouwer

van der Mast

Schalm

. Suicide associated with alfa-interferon therapy for chronic viral hepatitis. J Hepatol 1994;21:241–3.

62.

Iancu

Sverdlik

Dannon

Lepkifker

. Bipolar disorder associated with interferon-alpha treatment. Postgrad Med J 1997;73:834–5.

63.

Van Thiel

Friedlander

Molloy

Fagiuoli

Kania

Caraceni

. Interferon-alpha can be used successfully in patients with hepatitis C virus—positive chronic hepatitis who have a psychiatric illness. Eur J Gastroenterol Hepatol 1995;7:165–8.

64.

Strite

Valentine

Meyers

. Manic episodes in two patients treated with interferon alpha. J Neuropsychiatry Clin Neurosci 1997;9: 273–6.

65.

Monji

Yoshida

Tashiro

Hayashi

Tashiro

. A case of persistent manic depressive illness induced by interferon—alfa in the treatment of chronic hepatitis C (letter). Psychosomatics 1998;39:562–4.

66.

Carpiniello

Orru

Baita

Pariante

Farci

. Mania induced by withdrawal of treatment with interferon alfa (letter). Arch Gen Psychiatry 1998;55:88–9.

67.

Liberati

Biscottini

Fizzotti

Schippa

DeAngelis

Senatore

A Phase I study of human natural interferon-β in cancer patients. J Interferon Res 1989;9:339–48.

68.

Okada

. Interferon-induced depression: Just one of Bonhoeffer's exogene Reaktionstypen or a clue to understanding psychoimmunological aspects of depression? J Mol Med 1995;73:99–100.

69.

Licinio

Kling

Hauser

. Cytokines and brain function: Relevance to interferon-α -induced mood and cognitive changes. Semin Oncol 1998;25(suppl 1):30–8.

70.

Smith

. The macrophage theory of depression. Medical Hypotheses 1991;35:298–306.

71.

Daniels

Meager

Eddleston

ALWF

Alexander

GJM

Williams

. Spontaneous production of tumour necrosis factor α and interleukin-1β during interferon-α treatment of chronic HBV infection. Lancet 1990;335:875–7.

72.

Maes

Smith

Scharpe

. The monocyte-T-lymphocyte hypothesis of major depression. Psychoneuroendocrinology 1995;20:111–6.

73.

Crosmit

EPM

Heyligenberg

Endert

Sauerwein

. Acute effects of interferon-α administration on thyroid hormone metabolism in healthy men. J Clin Endocrinol Metab 1995;80:3140–4.

74.

Pfefferkorn

. Interferon-γ blocks the growth of Toxoplasma gondii in human fibroblasts by inducing the host cells to degrade tryptophan. Proc Natl Acad Sci U S A 1984;81:908–12.

75.

Werner-Felmayer

Werner

Fuchs

Hausen

Reibnegger

Wachter

. Characteristics of interferon induced tryptophan metabolism in human cells in vitro. Biochim Biophys Acta 1989;1012:140–7.

76.

Kugaya

Kagaya

Uchitomi

Yokota

Yamawaki

. Effect of interferon-α on DOI-induced wet-dog shakes in rats. J Neural Transm 1996;103:947–55.

77.

Morikawa

Sakai

Obara

Saito

. Effects of interferon-α, interferon-γ and cAMP on the transcriptional regulation of the serotonin transporter. Eur J Pharmacol 1998;349:317–24.

78.

Maes

Scharpe

Meltzer

Okayli

Bosmans

D'Hondt

Increased neopterin and interferon-gamma secretion and lower availability of L-tryptophan in major depression: Further evidence for an immune response. Psychiatry Res 1994;54:143–60.

79.

Kagaya

Uchitomi

Takezaki

Fukue

Tsukano

Kugaya

Plasma levels of cyclic GMP, immune parameters and depressive status during interferon therapy. A prospective study in Japan. Neuropsychobiology 1997;35:128–31.

80.

Taylor

Grossberg

. The effects of interferon-α on the production and the action of other cytokines. Semin Oncol 1998;25(suppl 1):23–9.

81.

Johnson

Fisher

Fenaughty

Theno

. Hepatitis C virus and depression in drug users. Am J Gastroenterol 1998;93:785–9.

82.

Hunt

Dominitz

Bute

Waters

Blasi

Williams

. Effects of interferon-α treatment of hepatitis C on health-related quality of life. Dig Dis Sci 1997;42:2482–8.

83.

Caraceni

Gangeri

Martini

Belli

Brunelli

Baldini

Neurotoxicity of interferon-α in melanoma therapy: Results from a randomized controlled trial. Cancer 1998;83:482–9.

84.

Mapou

Law

Wagner

Malone

Skillman

. Neuropsychological effects of interferon alfa-n3 treatment in asymptomatic human immunodeficiency virus-1–infected individuals. J Neuropsychiatry Clin Neurosci 1996;8:74–81.

85.

Malaguarnera

Di Fazio

Restuccia

Pistone

Ferlito

Rampello

. Interferon alpha—induced depression in chronic hepatitis C patients: Comparison between different types of interferon alpha. Neuropsychobiology 1998;37:93–7.

86.

Pariante

Orru

Baita

Farci

Carpiniello

. Treatment with interferon-α in patients with chronic hepatitis and mood and anxiety disorders (letter). Lancet 1999;354:131–2.

87.

Liberati

Biagini

Perticoni

Ricci

D'Alessandro

Senatore

Electrophysiological and neurophysiological functions in patients treated with interferon-β. J Interferon Res 1990;10:613–9.

88.

Capuron

Ravaud

. Prediction of the depressive effects of interferon alfa therapy by the patient's initial affective state (letter). N Engl J Med 1999;340:1370.

89.

Mulder

Ang

Chapman

Ross

Stevens

Edgar

. Interferon treatment is not associated with a worsening of psychiatric symptoms in patients with hepatitis C. J Gastroenterol Hepatol 2000;15:300–3.

90.

Trask

Esper

Riba

Redman

. Psychiatric side effects of interferon therapy: Prevalence, proposed mechanisms, and future directions. J Clin Oncol 2000;18:2316–26.

91.

Schubert

DSP

Foliart

. Increased depression in multiple sclerosis patients. A meta-analysis. Psychosomatics 1993;34:124–30.

92.

Feinstein

. Depression associated with multiple sclerosis: An etiological conundrum. Can J Psychiatry 1995;40:573–5.

93.

Woo

Burnakis

. Interferon alfa in the treatment of chronic viral hepatitis B and C. Ann Pharmacother 1997;31:330–7.